Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Saracatinib Trial to Prevent FOP (STOPFOP)
2019-003324-20Phase 2Active
- Sponsor
- VU University Medical Center
- Start
- Oct 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, single-arm trial of saracatinib in fibrodysplasia ossificans progressiva (FOP), sponsored by VU University Medical Center. Primary endpoint: Primary efficacy endpoint. Started Oct 2019; status: active.
02
Drugs
saracatinib
03
Conditions
fibrodysplasia ossificans progressiva (FOP)
Beyond the preview
Go deeper on 2019-003324-20.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-003324-20.